Access Purchased Content

Addiction Treatment
Addiction Treatment RSS Feed RSS

Clinical Update

Understanding Viral Hepatitis in the Context of Addiction Psychiatry

April 1, 2025

Danielle Herman. Case Western Reserve University School of Medicine, Cleveland, OH.

Raquel Rozner, MD. Gastroenterology Associates, PC, Stratford, CT; Bridgeport Hospital/Yale New Haven Health, Bridgeport, CT.

Akhil Anand, MD. Department of Psychiatry and Psychology, Cleveland Clinic; Department of Psychiatry, University Hospitals Medical Center, Cleveland, OH.

Ms. Herman, Dr. Rozner, and Dr. Anand have no financial relationships with companies related to this material. 

Hepatitis B and C are highly prevalent in people who use drugs and can result in significant morbidity and mortality due to progressive liver disease. In this article, we cover all the basics, including screening, symptoms, and relevant laboratory testing. We give tips to provide your patients on hepatitis prevention and when to refer them to specialists for treatment. 


Read More
Fact Sheet

Buprenorphine Monotherapy (Subutex, others)

January 1, 2025
Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

  • Buprenorphine (Subutex, available now only as generic) is the active ingredient in Suboxone (buprenorphine/naloxone) and is responsible for the effectiveness of the combination medication in opioid use disorder (OUD). 



    • Read More
    Fact Sheet

    Buprenorphine Extended-Release Injection Monotherapy (Brixadi, Sublocade)

    January 1, 2025
    Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

    Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
    Full Fact Sheet Editorial Information

  • Extended-release injectable formulations of buprenorphine allow patients to receive doses weekly, monthly, or every eight weeks for patients maintained on a low dose—which improves medication adherence.



    • Read More
    Clinical Guidance

    Neonatal Opioid Withdrawal Syndrome: Recognition and Management

    January 1, 2025
    Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

    Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
    Full Fact Sheet Editorial Information

  • Neonatal opioid withdrawal syndrome (NOWS), sometimes used interchangeably with the term neonatal abstinence syndrome (NAS), results from prenatal opioid exposure.



    • Read More
    Carlat Total Access Subscriptions: Get access to every article on the website.

    Complete access to every article you search on the website.

    Shop for Total Access
    Free Psychiatry Updates
    The latest unbiased psychiatric information sent to your inbox.
    Specify Your Interests
    Featured Book
    Featured Video
    Featured Podcast
    Recommended

    About

    Shop Online

    Newsletters

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2026 Carlat Publishing, LLC and Affiliates, All Rights Reserved.